303 related articles for article (PubMed ID: 25384424)
1. N-Acylethanolamine-hydrolyzing acid amidase inhibition increases colon N-palmitoylethanolamine levels and counteracts murine colitis.
Alhouayek M; Bottemanne P; Subramanian KV; Lambert DM; Makriyannis A; Cani PD; Muccioli GG
FASEB J; 2015 Feb; 29(2):650-61. PubMed ID: 25384424
[TBL] [Abstract][Full Text] [Related]
2. N-acylethanolamine-hydrolyzing acid amidase and fatty acid amide hydrolase inhibition differentially affect N-acylethanolamine levels and macrophage activation.
Alhouayek M; Bottemanne P; Makriyannis A; Muccioli GG
Biochim Biophys Acta Mol Cell Biol Lipids; 2017 May; 1862(5):474-484. PubMed ID: 28065729
[TBL] [Abstract][Full Text] [Related]
3. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation.
Solorzano C; Zhu C; Battista N; Astarita G; Lodola A; Rivara S; Mor M; Russo R; Maccarrone M; Antonietti F; Duranti A; Tontini A; Cuzzocrea S; Tarzia G; Piomelli D
Proc Natl Acad Sci U S A; 2009 Dec; 106(49):20966-71. PubMed ID: 19926854
[TBL] [Abstract][Full Text] [Related]
4. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
[TBL] [Abstract][Full Text] [Related]
5. N-Acylethanolamine-Hydrolyzing Acid Amidase Inhibition, but Not Fatty Acid Amide Hydrolase Inhibition, Prevents the Development of Experimental Autoimmune Encephalomyelitis in Mice.
Bottemanne P; Guillemot-Legris O; Paquot A; Masquelier J; Malamas M; Makriyannis A; Alhouayek M; Muccioli GG
Neurotherapeutics; 2021 Jul; 18(3):1815-1833. PubMed ID: 34235639
[TBL] [Abstract][Full Text] [Related]
6. Harnessing the anti-inflammatory potential of palmitoylethanolamide.
Alhouayek M; Muccioli GG
Drug Discov Today; 2014 Oct; 19(10):1632-9. PubMed ID: 24952959
[TBL] [Abstract][Full Text] [Related]
7.
Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
[No Abstract] [Full Text] [Related]
8. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
[TBL] [Abstract][Full Text] [Related]
9. Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages.
Sun YX; Tsuboi K; Zhao LY; Okamoto Y; Lambert DM; Ueda N
Biochim Biophys Acta; 2005 Oct; 1736(3):211-20. PubMed ID: 16154384
[TBL] [Abstract][Full Text] [Related]
10. Interferon γ treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells.
Alhouayek M; Rankin L; Gouveia-Figueira S; Fowler CJ
Br J Pharmacol; 2019 May; 176(10):1470-1480. PubMed ID: 29313885
[TBL] [Abstract][Full Text] [Related]
11. Diacerein is a potent and selective inhibitor of palmitoylethanolamide inactivation with analgesic activity in a rat model of acute inflammatory pain.
Petrosino S; Ahmad A; Marcolongo G; Esposito E; Allarà M; Verde R; Cuzzocrea S; Di Marzo V
Pharmacol Res; 2015 Jan; 91():9-14. PubMed ID: 25447594
[TBL] [Abstract][Full Text] [Related]
12. Adelmidrol increases the endogenous concentrations of palmitoylethanolamide in canine keratinocytes and down-regulates an inflammatory reaction in an in vitro model of contact allergic dermatitis.
Petrosino S; Puigdemont A; Della Valle MF; Fusco M; Verde R; Allarà M; Aveta T; Orlando P; Di Marzo V
Vet J; 2016 Jan; 207():85-91. PubMed ID: 26639824
[TBL] [Abstract][Full Text] [Related]
13. N-acylethanolamine metabolism with special reference to N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Ueda N; Tsuboi K; Uyama T
Prog Lipid Res; 2010 Oct; 49(4):299-315. PubMed ID: 20152858
[TBL] [Abstract][Full Text] [Related]
14. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide.
Fowler CJ; Jonsson KO; Tiger G
Biochem Pharmacol; 2001 Sep; 62(5):517-26. PubMed ID: 11585048
[TBL] [Abstract][Full Text] [Related]
15. The N-acylethanolamine-hydrolyzing acid amidase (NAAA).
Tsuboi K; Takezaki N; Ueda N
Chem Biodivers; 2007 Aug; 4(8):1914-25. PubMed ID: 17712833
[TBL] [Abstract][Full Text] [Related]
16. Advances in the discovery of N-acylethanolamine acid amidase inhibitors.
Bandiera T; Ponzano S; Piomelli D
Pharmacol Res; 2014 Aug; 86():11-7. PubMed ID: 24798679
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
[TBL] [Abstract][Full Text] [Related]
18. Palmitoylethanolamide, a naturally occurring lipid, is an orally effective intestinal anti-inflammatory agent.
Borrelli F; Romano B; Petrosino S; Pagano E; Capasso R; Coppola D; Battista G; Orlando P; Di Marzo V; Izzo AA
Br J Pharmacol; 2015 Jan; 172(1):142-58. PubMed ID: 25205418
[TBL] [Abstract][Full Text] [Related]
19. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
[TBL] [Abstract][Full Text] [Related]
20. Inflammation-restricted anti-inflammatory activities of a N-acylethanolamine acid amidase (NAAA) inhibitor F215.
Li Y; Zhou P; Chen H; Chen Q; Kuang X; Lu C; Ren J; Qiu Y
Pharmacol Res; 2018 Jun; 132():7-14. PubMed ID: 29572189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
